BRAF and melanoma: In another real‐world study of treatment‐naïve patients with BRAF‐mutant advanced melanoma, Whitman et al (2019) found that 57.0% of the BRAF‐mutant cohort received only 1L, 28.0% 1L and 2L, and 15.0% 3L+.26